NUVA — NuVasive Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedMid Cap
- $2.08bn
- $2.80bn
- $1.20bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.85 | ||
| PEG Ratio (f) | 0.49 | ||
| EPS Growth (f) | 57.95% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.55 | ||
| Price to Tang. Book | 36.79 | ||
| Price to Free Cashflow | 96.18 | ||
| Price to Sales | 1.83 | ||
| EV to EBITDA | 12.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.61% | ||
| Return on Equity | 2.4% | ||
| Operating Margin | 6.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,101.71 | 1,168.07 | 1,050.58 | 1,138.99 | 1,201.94 | 1,286.07 | 1,369.5 | 3.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -28.71 | +33.54 | n/a | n/a | n/a | +241.04 | +16.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NuVasive, Inc. is a medical technology company. The Company is focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. It offers a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for the spine and specialized orthopedic procedures. It also designs and sell expandable growing rod implant systems for the treatment of early-onset scoliosis that can be non-invasively lengthened after implantation with incremental adjustments via an external remote controller using magnetic technology called MAGneticExternal Control (MAGEC). It operates in more than 50 countries serving surgeons, hospitals, and patients.
Directors
- Daniel Wolterman NEC (64)
- J. Christopher Barry CEO (48)
- Matthew Harbaugh CFO (50)
- Andrew Morton CHO (56)
- Brent Boucher EVP (54)
- Massimo Calafiore EVP (49)
- Nathaniel Sisitsky SVP (47)
- Dale Wolf SVP (41)
- Juliet Cunningham VPR
- Vickie Capps IND (59)
- John DeFord IND (60)
- Robert Friel IND (65)
- R. Scott Huennekens IND (56)
- Siddhartha Kadia IND (51)
- Leslie Norwalk IND (55)
- Amy Raimundo IND (48)
- Donald Rosenberg IND (70)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- July 21st, 1997
- Public Since
- May 13th, 2004
- No. of Shareholders
- 66
- No. of Employees
- 3,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 52,449,167
- Address
- 7475 Lusk Blvd, SAN DIEGO, 92121
- Web
- https://www.nuvasive.com/
- Phone
- +1 8589091800
- Contact
- Juliet Cunningham
- Auditors
- Ernst & Young LLP
Upcoming Events for NUVA
Q2 2023 NuVasive Inc Earnings Call
Q3 2023 NuVasive Inc Earnings Release
Similar to NUVA
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Acutus Medical
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
FAQ
What is the NuVasive share price?
As of Today at 13:16 UTC, shares in NuVasive are trading at $42.54. This share price information is delayed by 15 minutes.
How has the NuVasive share price performed this year?
Shares in NuVasive last closed at $42.54 and the price had moved by -17.32% over the past 365 days. In terms of relative price strength the NuVasive share price has underperformed the S&P500 Index by -29.02% over the past year.
What are the analyst and broker recommendations for NuVasive?
The overall consensus recommendation for NuVasive is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the NuVasive dividend yield?
NuVasive does not currently pay a dividend.
Does NuVasive pay a dividend?
NuVasive does not currently pay a dividend.
When does NuVasive next pay dividends?
NuVasive does not currently pay a dividend.
How do I buy NuVasive shares?
To buy shares in NuVasive you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NuVasive?
As of the previous close price of $42.54, shares in NuVasive had a market capitalisation of $2.26bn.
Where are NuVasive shares listed?
Here are the trading details for NuVasive:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NUVA
What kind of share is NuVasive?
Based on an overall assessment of its quality, value and momentum NuVasive is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NuVasive share price forecast for 2023?
The analyst consensus target price for shares in NuVasive is $48.40. That is 13.77% above the last closing price of $42.54.
Analysts covering NuVasive currently have a consensus Earnings Per Share (EPS) forecast of $2.17 for the next financial year.
What is the trend in the NuVasive share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NuVasive. Over the past six months, its share price has underperformed the S&P500 Index by -15.66%.
As of the last closing price of $42.54, shares in NuVasive were trading +2.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NuVasive PE Ratio?
The NuVasive PE ratio based on its reported earnings over the past 12 months is 17.85. The shares last closed at $42.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NuVasive?
NuVasive's management team is headed by:
- Daniel Wolterman - NEC
- J. Christopher Barry - CEO
- Matthew Harbaugh - CFO
- Andrew Morton - CHO
- Brent Boucher - EVP
- Massimo Calafiore - EVP
- Nathaniel Sisitsky - SVP
- Dale Wolf - SVP
- Juliet Cunningham - VPR
- Vickie Capps - IND
- John DeFord - IND
- Robert Friel - IND
- R. Scott Huennekens - IND
- Siddhartha Kadia - IND
- Leslie Norwalk - IND
- Amy Raimundo - IND
- Donald Rosenberg - IND